Analysts Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) Will Announce Earnings of -$1.57 Per Share

Brokerages expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to report ($1.57) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for TRACON Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.64) and the highest is ($1.50). TRACON Pharmaceuticals posted earnings of ($2.60) per share during the same quarter last year, which indicates a positive year over year growth rate of 39.6%. The firm is scheduled to report its next earnings report on Thursday, February 27th.

On average, analysts expect that TRACON Pharmaceuticals will report full-year earnings of ($7.75) per share for the current fiscal year, with EPS estimates ranging from ($7.89) to ($7.60). For the next year, analysts anticipate that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($4.48) to $2.00. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow TRACON Pharmaceuticals.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03.

A number of research firms have weighed in on TCON. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of TRACON Pharmaceuticals in a report on Thursday, November 7th. ValuEngine raised shares of TRACON Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research upgraded shares of TRACON Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $4.88.

TCON traded up $0.02 during midday trading on Friday, hitting $3.07. The stock had a trading volume of 18,664 shares, compared to its average volume of 30,458. The company has a market cap of $9.64 million, a P/E ratio of -0.24 and a beta of 2.24. The business has a fifty day moving average of $2.07 and a 200 day moving average of $0.93. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.58 and a current ratio of 1.58. TRACON Pharmaceuticals has a 1 year low of $2.78 and a 1 year high of $17.30.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP acquired a new stake in shares of TRACON Pharmaceuticals during the 2nd quarter worth about $26,000. Wedbush Securities Inc. purchased a new stake in shares of TRACON Pharmaceuticals during the 2nd quarter worth approximately $32,000. Finally, Renaissance Technologies LLC boosted its stake in shares of TRACON Pharmaceuticals by 17.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,209,203 shares of the biopharmaceutical company’s stock worth $822,000 after acquiring an additional 179,718 shares in the last quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.

Featured Story: How can investors find ex-dividend dates?

Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.